1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Cipla Gears To Step In With Gx Kaletra Supplies For nCoV

 
• By Anju Ghangurde

Over half a dozen generic versions of AbbVie's Kaletra, currently part of treatment guidelines in China for nCoV-2019, are already on the Indian market and drug maker Cipla says it can make available around 12 million tablets of the combination. India has meanwhile just confirmed its first case of the coronavirus infection.

Map_Wuhan
India Reports First Case Of Coronavirus • Source: Shutterstock

At least half a dozen Indian companies already have versions of AbbVie Inc.’s HIV combination drug Kaletra (lopinavir and ritonavir; also sold as Aluvia) on the domestic market and one of them, Cipla Ltd., has expressed its readiness to move in quickly with supplies to tackle the growing number of infections globally with the novel coronavirus nCoV-2019.

Cipla’s chairman Yusuf Hamied told Scrip that the company has “material” to make about 12 million tablets of its product (sold as Lopimune in India) and will, in an emergency,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Therapy Areas

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.